Macular degeneration, or age-related macular degeneration (AMD), affects about 8% of the population in France and remains the leading cause of visual disability after age 50, according to the French research institute Inserm. It damages the macula, the area of the retina that handles reading and face recognition. No treatment cures it, but five modifiable factors weigh on its onset and its speed of progression: smoking, diet, macular pigments, physical activity and screening. Here is what European cohorts and the AREDS trials measure for each one, with the figures and the practical steps that follow from them.
In brief – Macular degeneration (AMD) is a degenerative disease of the macula that gradually destroys central vision after age 50, without ever causing total blindness. Five levers have solid evidence behind them. Smoking multiplies the risk by 2 to 3 in current smokers (Thornton 2005). Strong adherence to the Mediterranean diet cuts the risk of the advanced form by 41% (Merle 2019, 4,996 participants). Lutein and zeaxanthin, from green vegetables or from the AREDS2 formula, slow progression at the intermediate stages. Regular physical activity goes with a 41% lower likelihood of late AMD (McGuinness 2017). A regular dilated eye exam from age 55, completed by the Amsler grid self-test, allows early treatment of the wet form, which responds to anti-VEGF injections. None of these levers reverses existing damage: they slow the process down.
Macular degeneration: definition and stages of the disease
AMD is the pathological aging of the macula, an area 5 mm (0.2 in) across at the center of the retina, where the cones responsible for sharp vision are concentrated. In France, according to Inserm, macular degeneration affects 1% of people aged 50 to 55, about 10% of those aged 65 to 75 and 25 to 30% of people over 75, all forms combined. Peripheral vision stays intact, which is why, as the National Eye Institute points out, AMD does not cause complete blindness and a patient can still get around alone even at an advanced stage.
Ophthalmologists distinguish three stages. Early age-related maculopathy corresponds to the first deposits, called drusen, without any visual complaint. The intermediate stage combines large drusen and pigment abnormalities. Late AMD takes two forms: atrophic (so-called dry) AMD, which is slow and in which the photoreceptors disappear over 5 to 10 years, and neovascular (so-called wet) AMD, which is fast and in which abnormal vessels leak under the macula. The European EYE-RISK cohort (Colijn et al., 2017) quantifies this progression with age.
| Age group | Early AMD (maculopathy) | Late AMD |
|---|---|---|
| 55 to 59 years | 3.5% | 0.1% |
| 85 years and over | 17.6% | 9.8% |
| 2040 projection (Europe) | 14.9 to 21.5 million people | 3.9 to 4.8 million people |
Worldwide, the meta-analysis by Wong et al. (2014), covering 129,664 people, puts prevalence at 8.69% between ages 45 and 85 and projects 288 million cases in 2040. The World Health Organization ranks this degeneration among the leading causes of visual impairment that glasses cannot correct.
Mechanism: why the macula ages faster than the rest of the eye
The macula wears out because it combines three stresses that no other tissue endures to this degree: record oxygen consumption, continuous exposure to light and a membrane rich in polyunsaturated fatty acids that oxidize easily. Every day, the photoreceptors renew the tips of their outer segments, and the retinal pigment epithelium (RPE) has to digest this debris. With age, that digestion becomes incomplete.
The undegraded residues then build up in two forms. Lipofuscin piles up inside RPE cells, where it amplifies oxidative stress under the effect of light. Drusen settle beneath the RPE: they are clumps of lipids, proteins and fragments of the complement system. This failure of cellular recycling belongs to the loss of proteostasis, one of the twelve fundamental mechanisms of aging. The review by Fleckenstein et al. (2021) in Nature Reviews Disease Primers describes this loop between oxidative stress, local inflammation and deposits.
The known risk factors for macular degeneration fit into this mechanism:
- Age: incidence climbs from 0.3 per 1,000 people between ages 55 and 59 to 36.7 per 1,000 beyond age 90 (Inserm).
- Genetics: variants of the CFH gene (complement factor H) and of the ARMS2/HTRA1 region are the most common in Europe.
- Smoking: it raises retinal oxidative stress and reduces choroidal blood flow.
- A diet low in macular pigments (lutein, zeaxanthin) and in long-chain omega-3s.
- Cardiovascular factors: high blood pressure and obesity, with a more modest weight in the cohorts.
What the science says: the 5 levers and their numbers
Smoking remains the most powerful modifiable factor. The review by Thornton et al. (2005), which compiles 17 epidemiological studies, finds a risk of AMD multiplied by 2 to 3 in current smokers compared with people who never smoked, with a dose-response relationship. The risk falls after quitting, without immediately matching that of a never-smoker. For a smoker over 50, quitting therefore remains the best documented step to prevent macular degeneration.
The Mediterranean diet comes second. In the EYE-RISK consortium, Merle et al. (2019) followed 4,996 participants from the Rotterdam and Bordeaux (Alienor study) cohorts: people with a high Mediterranean score (6 to 9 out of 9) had a 41% lower risk of advanced AMD than those with a low score (hazard ratio 0.59, 95% confidence interval 0.37 to 0.95). Fish carries much of this result: the meta-analysis by Chong et al. (2008), on 88,974 people, links two weekly servings of fish to a 33% drop in late AMD (odds ratio 0.67).
Macular pigments, lutein and zeaxanthin, form the third lever, with an important nuance. The AREDS trial (AREDS Research Group, 2001), run on 3,640 participants over 6.3 years, showed that an antioxidant plus zinc formula reduced progression to advanced AMD by 28% (odds ratio 0.72) in patients already at the intermediate stage. The AREDS2 trial (2013, 4,203 participants) then replaced beta-carotene with 10 mg of lutein and 2 mg of zeaxanthin, because beta-carotene doubled lung cancers in former smokers (2.0% versus 0.9%). The 10-year follow-up published by Chew et al. (2022) confirms a 15% lower risk of late AMD with lutein and zeaxanthin compared with beta-carotene (hazard ratio 0.85), while omega-3 capsules (DHA + EPA) showed no effect (hazard ratio 1.01). Fish protects in the cohorts, the capsule does not: both results stand side by side.
Physical activity is the fourth lever. The meta-analysis by McGuinness et al. (2017), pooling 9 studies, links a high activity level to a 41% lower risk of late AMD (odds ratio 0.59 in 28,854 people) and an 8% lower risk of the early form (odds ratio 0.92 in 38,112 people). These data are observational: active people smoke less and eat better, which explains part of the gap. The specific effect of movement most likely runs through choroidal circulation and lower systemic inflammation.
Screening closes the list, because it changes the prognosis without acting on the cause. The AREDS authors recommend a dilated eye exam after age 55. Inserm notes that once one eye is affected, the second follows in 10% of cases within one year and in 42% of cases within five years. In wet AMD, only a few weeks separate the first visual distortions from permanent loss, whereas intravitreal anti-VEGF injections stabilize vision in most patients treated early. Colijn et al. (2017) attribute the improvement in visual acuity seen in Europe since 2006 to the arrival of these treatments and to healthier lifestyles.
| Lever | Type of evidence | Measured effect | Source |
|---|---|---|---|
| Quitting smoking | 17 epidemiological studies | Risk x2 to x3 in current smokers | Thornton 2005 |
| Mediterranean diet | 2 prospective cohorts, 4,996 people | Advanced AMD: risk reduced by 41% | Merle 2019 |
| Lutein + zeaxanthin (AREDS2 formula) | Randomized trial, 4,203 people, 10-year follow-up | Late AMD: risk reduced by 15% vs beta-carotene | Chew 2022 |
| Physical activity | Meta-analysis of 9 studies | Late AMD: risk reduced by 41% | McGuinness 2017 |
| Screening and Amsler grid | Expert recommendation, cohort data | Early anti-VEGF treatment of wet AMD | AREDS 2001, Colijn 2017 |
In practice: which lever for your situation
Priorities change with the stage, and the AREDS2 formula applies to one precise profile only. In a person with no lesions, supplements have never shown a preventive effect: diet, movement and quitting smoking do the work. In a patient diagnosed at the intermediate stage by an ophthalmologist, the AREDS2 formula becomes the only validated supplementation, on prescription and with follow-up.
| Profile | Priority no. 1 | Priority no. 2 | AREDS2 supplements |
|---|---|---|---|
| Over 50, no lesions | Quit smoking if you smoke | Mediterranean plate, 150 minutes of activity per week | Not justified |
| Direct family history | Dilated eye exam from age 50, then every 2 years | Green vegetables and oily fish twice a week | Not justified without lesions |
| Early maculopathy (small drusen) | Monthly Amsler grid | Mediterranean diet, physical activity | Benefit not shown at this stage |
| Intermediate AMD, or advanced AMD in one eye | Close ophthalmological follow-up | AREDS2 formula on medical advice | Risk of the late form reduced by 15 to 28% |
These levers overlap with those for other organs. The Mediterranean diet protects the macula through the same nutrients as the heart: vegetables, legumes, olive oil and fish. Dietary carotenoids concentrate in the macula, where lutein and zeaxanthin filter blue light and neutralize free radicals. As for tobacco, its ten years of life lost count the retina among the tissues it damages fastest. To follow the next studies on the macula, the UltraSanté health newsletter sums up each week the publications that matter.
Protocol: 5 concrete steps to put in place
The steps below follow directly from the studies cited. They settle in within a few weeks and need no equipment, apart from a printed Amsler grid.
- Stop smoking, with support (a smoking cessation specialist, nicotine replacement): this is the lever that weighs most on the risk of macular degeneration, and the benefit grows with each smoke-free year.
- Eat leafy green vegetables every day: cooked spinach provides about 11 mg of lutein and zeaxanthin per 100 g (3.5 oz), kale about 9 mg. Egg yolk contains less, but its fatty matrix improves absorption of the pigments.
- Eat oily fish twice a week (sardines, mackerel, herring, salmon): this is the frequency linked to a 33% drop in late forms in the Chong 2008 meta-analysis.
- Move at least 150 minutes per week through brisk walking, cycling or swimming: the high activity level in the cohorts analyzed by McGuinness 2017 matches this recommended threshold.
- Test your vision once a month with the Amsler grid, one eye after the other, at reading distance: any wavy or broken line or blurred area calls for an appointment within the week. Schedule a dilated eye exam every two years from age 55, every year if you have a family history.
Two precautions complete this protocol:
- Smokers and former smokers should refuse any supplement containing beta-carotene, because of the lung cancer risk found in AREDS2.
- The AREDS2 formula (500 mg of vitamin C, 400 IU of vitamin E, 80 mg of zinc, 2 mg of copper, 10 mg of lutein, 2 mg of zeaxanthin) is taken on medical advice, at a precise stage, never as prevention in a person without lesions.
Frequently asked questions about macular degeneration
How can you tell if you have early macular degeneration?
The first stages cause no symptoms: only a dilated eye exam or optical coherence tomography (OCT) reveals the drusen. The signs that appear later are a distortion of straight lines (metamorphopsia), a greater need for light when reading and a blurred spot at the center of the visual field. The Amsler grid, tested one eye at a time, detects these distortions at home. Any new abnormality warrants an ophthalmology appointment within the week.
What is the difference between dry AMD and wet AMD?
Dry (atrophic) AMD accounts for most late cases: the photoreceptors and the pigment epithelium disappear slowly, over 5 to 10 years, and no treatment restores the lost areas. Wet (neovascular) AMD progresses within weeks: abnormal vessels grow beneath the macula and leak fluid or blood. It is treated with intravitreal anti-VEGF injections, which stabilize vision if they start early.
Do lutein supplements prevent macular degeneration in a healthy person?
No, no trial has shown this. The AREDS and AREDS2 trials included only patients at the intermediate stage or with advanced AMD in one eye, and it is in them that the formula slows progression (risk reduced by 15 to 28%). In a person without lesions, the available data come from dietary cohorts: they link green vegetables and fish to a lower risk, with no equivalent evidence for capsules.
Why does fish protect when omega-3 capsules did not work?
The two results come from different methods. The Chong 2008 meta-analysis observes fish eaters, who often follow a diet that is more protective overall. The AREDS2 trial tested 1 g of DHA + EPA in capsule form in patients already affected, with no measurable effect at 5 or 10 years. Fish also provides vitamin D and replaces less favorable foods: the observed effect probably comes from the diet as a whole rather than from a single molecule.
At what age and how often should you have your retina checked?
A first dilated eye exam is advised around age 55, then every two years if no lesions are found. With a direct family history, checks start at age 50 and become annual. Once early maculopathy is diagnosed, the ophthalmologist sets the pace, often every 6 to 12 months, and monthly self-monitoring with the Amsler grid fills the gap between visits, because an affected eye puts the second one at risk in 42% of cases within five years.
Medical disclaimer. The information provided here is for informational purposes only and does not constitute medical advice. It does not replace a consultation. Ask a healthcare professional before changing your diet, taking dietary supplements or starting a new practice, especially if you have a medical condition, are pregnant or are under treatment. Dietary supplements do not replace a balanced diet or medical follow-up.
